2026 · 1st Quarter (Jan 1 - Mar 31)

DAIICHI SANKYO INC

Filed by DAIICHI SANKYO, INC..

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 20, 2026
Income: Not reported
Expenses: $130,000.00
Registrant: DAIICHI SANKYO, INC.
Client: DAIICHI SANKYO INC
Filing UUID: 5a9c12a8-0c15-4202-a0a8-ec2c09163f97
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration

Literal federal measure citations: H.R.946, H.R.2319

TAX · Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

MMM · Medicare/Medicaid

Issues related to the Medicare Drug Price Negotiation Program

CPT · Copyright/Patent/Trademark

Issues related to intellectual property rights

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.